stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Debt to equity
Haemonetics Corporation's debt to equity at the end of the quarter to 30 September 2026 was 1.2×, down 0.3× from fiscal 2026 (1.5×). Over the past ten years it has ranged from 0.1× (fiscal 2018) to 1.5× (fiscal 2026) — the current reading is the highest in ten years. That is above the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2026 | 1.5× | 36.46% |
| FY2025 | 1.1× | 35.09% |
| FY2024 | 0.8× | (9.88%) |
| FY2023 | 0.9× | 23.50% |
| FY2022 | 0.7× | (20.91%) |
| FY2021 | 0.9× | 81.38% |
| FY2020 | 0.5× | 7.79% |
| FY2019 | 0.5× | 511.14% |
| FY2018 | 0.1× | (76.96%) |
| FY2017 | 0.3× | (32.13%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 1.2× | (11.22%) |
| Jun 2026 | 1.4× | (8.80%) |
| Mar 2026 | 1.5× | 51.72% |
| Dec 2025 | 1.0× | (6.87%) |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TXG 10x Genomics compare | 0.0× |
| AXGN AxoGen, Inc. compare | 0.0× |
| BIO Bio-Rad Laboratories, Inc. compare | 0.2× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 0.2× |
| LIVN LivaNova PLC compare | 0.2× |
| ITGR Integer Holdings Corporation compare | 0.7× |
| BRKR Bruker Corporation compare | 0.7× |
| HAE Haemonetics Corporation | 1.2× |
| IRTC iRhythm Holdings, Inc. compare | 3.7× |
| Medical Devices industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement